Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database.
Mohamed HusseinWenhui WeiVera MasteyRobert J SanchezDegang WangDana J MurdockBoaz HirshbergDavid M WeinreichJessica J JalbertPublished in: BMJ open (2022)
The real-world effectiveness of CAS+IMD is consistent with the efficacy for reducing all-cause mortality or COVID-19-related hospitalisation reported in clinical trials. Effectiveness is maintained across patient subgroups, including those prone to breakthrough infections, and was effective against susceptible variants including Delta. .